newsfilter
← Latest News
Business Wire·

Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma

Bristol Myers Squibb (NYSE:BMY) and 2seventy bio, Inc. (NASDAQ:TSVT) today announced the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) will meet to review data supporting the